Lantheus (LNTH)
(Delayed Data from NSDQ)
$105.34 USD
-1.02 (-0.96%)
Updated Sep 5, 2024 04:00 PM ET
After-Market: $105.32 -0.02 (-0.02%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$105.34 USD
-1.02 (-0.96%)
Updated Sep 5, 2024 04:00 PM ET
After-Market: $105.32 -0.02 (-0.02%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Is Invesco S&P MidCap 400 GARP ETF (GRPM) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for GRPM
Should Invesco S&P MidCap 400 GARP ETF (GRPM) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for GRPM
Here's Why Investors Must Hold on to Centene (CNC) Stock Now
by Zacks Equity Research
Centene (CNC) is expected to benefit from expanding margins in the Marketplace business, contract wins in Medicaid, and improved Medicare Advantage Star ratings.
Why Lantheus Holdings (LNTH) is a Top Momentum Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Alcon (ALC) Achieves FDA 510(k) Clearance for Unity VCS and Unity CS
by Zacks Equity Research
Alcon (ALC) gets FDA 510(k) clearance for its Unity VCS and Unity CS. The company will start a thorough program to get real-world feedback before the systems' commercial launch in 2025.
Inspira (IINN) Unveils Business Targets for 2024-25
by Zacks Equity Research
Inspira (IINN) discloses business goals for 2024-25 with the rapid promotion of INSPIRA ART100 and the development of INSPIRA ART (Gen 2).
Zacks Industry Outlook Highlights Boston Scientific, ResMed, Lantheus and Haemonetics
by Zacks Equity Research
Boston Scientific, ResMed, Lantheus and Haemonetics are part of the Zacks Industry Outlook article.
New Strong Buy Stocks for June 21st
by Zacks Equity Research
ASYS, LAUR, ESLT, LNTH and LMAT have been added to the Zacks Rank #1 (Strong Buy) List on June 21, 2024.
Best Value Stocks to Buy for June 21st
by Zacks Equity Research
LAUR, ESLT and LNTH made it to the Zacks Rank #1 (Strong Buy) value stocks list on June 21, 2024.
Thermo Fisher (TMO) Unveils New Research Laboratory in WI
by Zacks Equity Research
Thermo Fisher (TMO) announces a new 72,500-square-foot clinical research laboratory building at its good manufacturing practices lab in Middleton, WI
Haemonetics (HAE) Expands VASCADE Line With New Limited Launch
by Zacks Equity Research
Haemonetics (HAE) expands its VASCADE portfolio with the limited market release of VASCADE MVP XL vascular closure device.
4 Medical Product Stocks to Buy From a Recovering Industry
by Indrajit Bandyopadhyay
Despite the ongoing macro headwinds, recovering demand for medical procedures and cost-cutting initiatives should support the Zacks Medical-Products industry. BSX, RMD, LNTH and HAE are well-poised to gain from the favorable factors.
Lantheus Holdings (LNTH) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Lantheus Holdings (LNTH) concluded the recent trading session at $81.13, signifying a -1.82% move from its prior day's close.
Lantheus (LNTH) Gains 33.3% YTD: What's Driving the Stock?
by Zacks Equity Research
Lantheus' (LNTH) focus on pipeline development raises optimism about the stock.
Compelling Reasons to Hold on to Cigna (CI) Stock for Now
by Zacks Equity Research
Cigna (CI) remains well-poised for growth on the back of improved pharmacy revenues in its Evernorth unit. Solid cash-generating abilities also enable it to tactically deploy capital.
Is Castle Biosciences (CSTL) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Castle Biosciences, Inc. (CSTL) and Lantheus Holdings (LNTH) have performed compared to their sector so far this year.
Don't Overlook These Highly Ranked Medical Stocks as Markets Rise
by Shaun Pruitt
With earnings estimate revisions on the rise for these top medical stocks, they certainly shouldn't be overlooked given their blazing historical performances.
New Strong Buy Stocks for June 12th
by Zacks Equity Research
RDNT, ESLT, CLS, LNTH and ASBFY have been added to the Zacks Rank #1 (Strong Buy) List on June 12, 2024.
Humana's (HUM) CenterWell Sets Foot in Asheville With New Centers
by Zacks Equity Research
Humana's (HUM) CenterWell Senior Primary Care announces the opening of two centers in Asheville, thus enhancing access to high-quality healthcare services and driving revenues of the CenterWell unit.
Lantheus Holdings (LNTH) Stock Drops Despite Market Gains: Important Facts to Note
by Zacks Equity Research
In the most recent trading session, Lantheus Holdings (LNTH) closed at $79.28, indicating a -0.78% shift from the previous trading day.
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
National Vision (EYE) Down 4% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
National Vision (EYE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Buy These 3 Beaten-Down MedTech Stocks for a Turnaround Soon
by Moumi Mondal
Investing in beaten-down stocks like OPCH, LNTH and HOLX can be profitable for investors in the long term.
The Zacks Rank Explained: How to Find Strong Buy Medical Stocks
by Zacks Equity Research
The Zacks Rank offers investors a way to easily find top-rated stocks and build a winning investment portfolio. Here's why you should take advantage.
Lantheus Holdings (LNTH) Upgraded to Strong Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Lantheus Holdings (LNTH) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.